ATE288447T1 - Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf) - Google Patents

Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)

Info

Publication number
ATE288447T1
ATE288447T1 AT96932325T AT96932325T ATE288447T1 AT E288447 T1 ATE288447 T1 AT E288447T1 AT 96932325 T AT96932325 T AT 96932325T AT 96932325 T AT96932325 T AT 96932325T AT E288447 T1 ATE288447 T1 AT E288447T1
Authority
AT
Austria
Prior art keywords
gdnf
cell line
glial cell
derived
treating alzheimer
Prior art date
Application number
AT96932325T
Other languages
English (en)
Inventor
Lawrence R Williams
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE288447T1 publication Critical patent/ATE288447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96932325T 1995-09-28 1996-09-23 Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf) ATE288447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/535,682 US5731284A (en) 1995-09-28 1995-09-28 Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
PCT/US1996/015305 WO1997011965A1 (en) 1995-09-28 1996-09-23 Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product

Publications (1)

Publication Number Publication Date
ATE288447T1 true ATE288447T1 (de) 2005-02-15

Family

ID=24135315

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96932325T ATE288447T1 (de) 1995-09-28 1996-09-23 Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)

Country Status (13)

Country Link
US (1) US5731284A (de)
EP (1) EP0852585B1 (de)
JP (1) JP4761409B2 (de)
AT (1) ATE288447T1 (de)
AU (1) AU711053B2 (de)
CA (1) CA2232789C (de)
DE (1) DE69634301T2 (de)
DK (1) DK0852585T3 (de)
ES (1) ES2237775T3 (de)
NZ (1) NZ319040A (de)
PT (1) PT852585E (de)
SI (1) SI0852585T1 (de)
WO (1) WO1997011965A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US6207656B1 (en) * 1997-05-22 2001-03-27 Cephalon, Inc. Vitamin D analogues and their neuronal effects
CA2301693A1 (en) * 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
AU758155B2 (en) 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
AU1822000A (en) * 1998-11-20 2000-06-13 Yale University Effects of gdnf and ngf on sodium channels in drg neurons
AU2001259453B2 (en) 2000-05-05 2006-08-31 Beth Israel Deaconess Medical Center Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
WO2002005634A2 (en) 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
KR20050021026A (ko) * 2001-06-15 2005-03-07 주식회사 장생도라지 장생도라지 추출물을 포함하는 면역계의 이상으로부터발생하는 질병의 예방 및 치료용 약제학적 조성물
US7150737B2 (en) * 2001-07-13 2006-12-19 Sci/Med Life Systems, Inc. Methods and apparatuses for navigating the subarachnoid space
US7455666B2 (en) * 2001-07-13 2008-11-25 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20060246036A1 (en) * 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20050225165A1 (en) * 2004-04-13 2005-10-13 Naik Sanjeev M Brake by-wire control system
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
EP1940471A1 (de) * 2005-10-28 2008-07-09 NsGene A/S Implantierbares biokompatibles immunisolatorisches vehikel zur abgabe von gdnf
WO2007059135A2 (en) * 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2291181B9 (de) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine zur Behandlung von depressionartigen Symptomen
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2485638B1 (de) 2009-10-07 2016-11-30 Endophys Holdings, LLC Medizinische druckerfassungsvorrichtungen
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
EP2646468B1 (de) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf-zusammensetzungen und ihre verwendung
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
US8999927B2 (en) * 2012-04-02 2015-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
WO2018089702A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
EP3628315A1 (de) 2018-09-28 2020-04-01 Université de Caen Normandie Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
AU1443095A (en) * 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
AU7117596A (en) 1997-04-17
EP0852585B1 (de) 2005-02-02
US5731284A (en) 1998-03-24
EP0852585A1 (de) 1998-07-15
WO1997011965A1 (en) 1997-04-03
AU711053B2 (en) 1999-10-07
DE69634301T2 (de) 2005-06-09
PT852585E (pt) 2005-04-29
ES2237775T3 (es) 2005-08-01
SI0852585T1 (en) 2005-06-30
DE69634301D1 (de) 2005-03-10
JPH11514860A (ja) 1999-12-21
CA2232789A1 (en) 1997-04-03
DK0852585T3 (da) 2005-05-09
JP4761409B2 (ja) 2011-08-31
CA2232789C (en) 2001-02-27
NZ319040A (en) 2001-02-23

Similar Documents

Publication Publication Date Title
ATE288447T1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
ATE194081T1 (de) Verfahren zur behandlung von verletzungen retinaler ganglione mit neurotrophischem faktor aus der glialzellinie (gdnf)
DE69913665D1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
LV10308A (lv) Ciliarais neirotropais faktors
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
ATE193020T1 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
EP0268973A3 (de) Verfahren zur Herstellung eines virussicheren, lagerstabilen und intravenös verträglichen Immunglobulin-G-Präparates
DE69029657D1 (de) Menschliches cytokin, interleukin-9
ATE311875T1 (de) Verfahren und mittel zur anregung des neuritwachstums
DE69810635D1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE153696T1 (de) Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
ATE141613T1 (de) Prozess zur darstellung von aspartam aus einem diketopiperazin sowie neue zwischenprodukte und derivate dafür
DE69319012D1 (de) Protein mit Knochenbildungs-Eigenschaften und Verfahren zu seiner Herstellung
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69607524D1 (de) Verfahren zur Herstellung von einem Bicyclohexanderivat
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
DE69627379D1 (de) Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
GR1002803B (el) Μεθοδος αποφυγης της κακοσμιας που αναπτυσσεται κατα την βοστρυχωση των μαλλιων με την εφαρμογη κυστεαμινης και αλλων θειουχων ενωσεων.
ATE13633T1 (de) Verfahren zur herstellung von hochgereinigtem antihaemophiliefaktor.
EP0238986A3 (de) Verfahren zur Herstellung eines den Blutgerinnungsfaktor VIII in ankonzentrierter Form enthaltenden Präparates
DE69122545D1 (de) Verfahren zur Herstellung von menschlichem Nervenwachstumsfaktor durch Genmanipulation
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.
ATE188384T1 (de) Verwendung von kollagen zur behandlung von krankhaften gelenkprozessen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0852585

Country of ref document: EP